• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    Capstar Special Purpose Acquisition Corp. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders

    1/12/22 4:09:39 PM ET
    $CPSR
    Business Services
    Finance
    Get the next $CPSR alert in real time by email
    0001805087 false 0001805087 2022-01-11 2022-01-11 0001805087 cpsr:UnitsEachConsistingOfOneShareOfClassaCommonStockAndOnehalfOfOneWarrantMember 2022-01-11 2022-01-11 0001805087 us-gaap:CommonClassAMember 2022-01-11 2022-01-11 0001805087 us-gaap:WarrantMember 2022-01-11 2022-01-11 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

     

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    WASHINGTON, DC 20549

     

    Form 8-K

     

    CURRENT REPORT PURSUANT TO

    SECTION 13 OR 15(d) OF THE

    SECURITIES EXCHANGE ACT OF 1934

     

    Date of report (Date of earliest event reported): January 12, 2022 (January 11, 2022)

     

    Capstar Special Purpose Acquisition Corp.

    (Exact Name of Registrant as Specified in Charter)

     

    Delaware   001-39362   84-4730610
    (State or Other Jurisdiction
    of Incorporation)
      (Commission
    File Number)
      (IRS Employer
    Identification No.)

     

    405 West 14th Street, Austin, TX 78701

    (Address of Principal Executive Offices) (Zip Code)

     

    (512) 340-7800

    (Registrant’s telephone number, including area code)

     

    Not Applicable

    (Former Name or Former Address, if Changed Since Last Report)

     

    Securities registered or to be registered pursuant to Section 12(b) of the Act:

     

    Title of Each Class Trading
    Symbol(s)
    Name of each exchange on which
    registered
    Units, each consisting of one share of Class A Common Stock and one-half of one Warrant CPSR.U The New York Stock Exchange
    Class A Common Stock, par value $0.0001 per share CPSR The New York Stock Exchange
    Warrants, each whole warrant exercisable for one share of Class A Common Stock at an exercise price of $11.50 CPSR WS The New York Stock Exchange

     

    Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

     

    ¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

     

    ¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

     

    ¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

     

    ¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

     

    Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).                                 Emerging Growth Company x

     

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  ¨

     

     

     

     

    Item 5.07. Submission of Matters to a Vote of Security Holders.

     

    On January 11, 2022, Capstar Special Purpose Acquisition Corp., a Delaware corporation (“CPSR” or the “Company”), held a special meeting of stockholders (the “Special Meeting”). At the Special Meeting, a total of 25,643,831 (74.3%) of CPSR’s issued and outstanding shares of common stock held of record as of November 15, 2021, the record date for the Special Meeting, were present either in person or by proxy, which constituted a quorum. CPSR’s stockholders voted on the following proposals at the Special Meeting, each of which was approved. The final vote tabulation for each proposal is set forth below.

     

      1.

    The Business Combination Proposal. To adopt a proposal to (a) adopt and approve the Business Combination Agreement, dated as of July 19, 2021, as amended on November 8, 2021 and December 30, 2021 (as may be further amended, supplemented or otherwise modified from time to time, the “Business Combination Agreement”), by and among CPSR, CPSR Gelesis Merger Sub, Inc., a Delaware corporation and a wholly-owned subsidiary of CPSR (“Merger Sub”), and Gelesis, Inc., a Delaware corporation (“Gelesis”), pursuant to which Merger Sub will merge with and into Gelesis, with Gelesis surviving the merger as a wholly-owned subsidiary of CPSR and (b) approve the Business Combination (as defined in the Business Combination Agreement). In connection with the Business Combination, CPSR will be renamed “Gelesis Holdings, Inc.” (“New Gelesis”) and Gelesis will retain its name “Gelesis, Inc.”

    Subject to the terms and conditions set forth in the Business Combination Agreement, at the Effective Time (as defined in the Business Combination Agreement), based on an implied equity value of $675 million:

     

      (i) each share of CPSR Class A common stock and CPSR Class B common stock issued and outstanding immediately prior to the Effective Time will become one share of New Gelesis common stock;
         
      (ii) each share of Gelesis outstanding as of immediately prior to the Effective Time will be automatically cancelled and extinguished and converted into a right to receive shares of New Gelesis common stock;

     

      (iii) each share of capital stock of Merger Sub issued and outstanding as of immediately prior to the Effective Time will be automatically cancelled and extinguished and converted into one share of New Gelesis common stock;
         
      (iv) all vested and unvested Gelesis options will be assumed by New Gelesis and thereafter be settled or exercisable for shares of New Gelesis common stock and each Gelesis warrant will be assumed by New Gelesis and thereafter be a warrant to purchase shares of New Gelesis common stock;
         
      (v) all vested and unvested Gelesis options will be assumed by New Gelesis and thereafter be settled or exercisable for shares of New Gelesis common stock and each Gelesis warrant will be assumed by New Gelesis and thereafter be a warrant to purchase shares of New Gelesis common stock; and
         
      (vi) each holder of shares of Gelesis common stock, Gelesis options and Gelesis warrants will receive its pro rata portion of 23,483,250 restricted earn out shares of New Gelesis common stock, which will vest (in part) in equal thirds if the trading price of New Gelesis common stock is greater than or equal to $12.50, $15.00 and $17.50, respectively, for any 20 trading days within any 30-trading day period on or prior to the date that is five years following the Effective Time and will also vest in connection with any Change of Control Transaction (as defined in the Business Combination Agreement) with respect to New Gelesis if the applicable thresholds are met in such Change of Control Transaction during the same five-year deadline.

     

    Votes For     Votes Against     Abstentions  
    24,835,281     807,450     1,100  

     

     

      2.

    The Charter Amendment Proposal. To adopt a proposal to approve, assuming the Business Combination Proposal is approved and adopted, a proposed amended and restated certificate of incorporation (the “Proposed Charter”), which will amend and restate CPSR’s current amended and restated certificate of incorporation (the “Current Charter”), and which Proposed Charter will be in effect when duly filed with the Secretary of the State of the State of Delaware in connection with the Closing (as defined in the Business Combination Agreement):

     

    Holders of CPSR Class A common stock, voting separately as a single class:

     

    Votes For   Votes Against   Abstentions  
    17,935,281   807,450   1,100  

     

        Holders of CPSR Class A common stock and CPSR Class B common stock, voting together as a single class:

     

    Votes For   Votes Against   Abstentions  
    24,835,281   807,450   1,100  

     

      3. The Advisory Charter Proposals. To adopt a proposal to approve, on a non-binding advisory basis, the following material differences between the Proposed Charter and the Current Charter, which are being presented in accordance with the requirements of the Securities and Exchange Commission as seven separate sub-proposals:
         
      a. Advisory Charter Proposal A – To change the corporate name of New Gelesis to “Gelesis Holdings, Inc.”:

     

    Votes For     Votes Against     Abstentions  
    24,463,729     807,450     372,652  

     

      b. Advisory Charter Proposal B – To increase CPSR’s capitalization so that it will have 900,000,000 authorized shares of common stock and 250,000,000 authorized shares of preferred stock:

     

    Votes For     Votes Against     Abstentions  
    23,040,986     2,230,193     372,652  

     

      c. Advisory Charter Proposal C – To divide the New Gelesis board of directors into three classes with staggered three-year terms:

     

    Votes For     Votes Against     Abstentions  
    22,450,379     2,820,800     372,652  

     

      d. Advisory Charter Proposal D – To provide that the removal of any director be only for cause and only by the affirmative vote of holders of at least 662∕3% of New Gelesis’ then outstanding shares entitled to vote at an election of directors:

     

    Votes For     Votes Against     Abstentions  
    22,466,285     2,804,894     372,652  

     

      e. Advisory Charter Proposal E – To provide that certain amendments to provisions of the Proposed Charter will require the affirmative vote of holders of at least 662∕3% of New Gelesis’ then outstanding shares of capital stock entitled to vote thereon, and the affirmative vote of at least 662∕3% of New Gelesis’ then outstanding shares of each class entitled to vote thereon as a class:

     

    Votes For     Votes Against     Abstentions  
    22,449,377     2,821,802     372,652  

     

     

      f. Advisory Charter Proposal F – To make New Gelesis’ corporate existence perpetual as opposed to CPSR’s corporate existence, which is required to be dissolved and liquidated twenty-four (24) months following the closing of its initial public offering, and to remove from the Proposed Charter the various provisions applicable only to blank check companies:

     

    Votes For     Votes Against     Abstentions  
    24,463,729     807,450     372,652  

     

      g. Advisory Charter Proposal G – To remove the provisions setting the Court of Chancery of the State of Delaware as the sole and exclusive forum for certain stockholder actions:

     

    Votes For     Votes Against     Abstentions  
    23,041,486     2,229,693     372,652  

     

      4. The NYSE Stock Issuance Proposal. To adopt a proposal to approve, assuming the Business Combination Proposal is approved and adopted, (a) the issuance of up to 96,876,625 newly issued shares of New Gelesis Common Stock in the Business Combination, which amount will be determined as described in the proxy statement/prospectus for the Special Meeting, and (b) the PIPE Financing (as defined in the Business Combination Agreement):

     

    Votes For     Votes Against     Abstentions  
    24,834,781     809,050     0  

     

      5. The Director Election Proposal. To approve, assuming the Business Combination Proposal is approved and adopted, the appointment of eight directors who, upon consummation of the Business Combination, will become directors of New Gelesis:

     

    Votes For     Votes Against     Abstentions  
    24,836,381     807,450     0  

     

      6. The Equity Incentive Plan Proposal. To adopt a proposal to approve, assuming the Business Combination Proposal is approved and adopted, the Gelesis Holdings, Inc. 2021 Stock Option and Incentive Plan, a copy of which is appended to the Business Combination Agreement as Exhibit h, which will become effective the day prior to the Closing:

     

    Votes For     Votes Against     Abstentions  
    24,817,383     826,448     0  

     

     

    SIGNATURES

     

    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

     

      CAPSTAR SPECIAL PURPOSE ACQUISITION CORP.
       
       
    Date: January 12, 2022 /s/ R. Steven Hicks
      Name: R. Steven Hicks
      Title: Chairman, Chief Executive Officer and Chief Financial Officer

     

     

    Get the next $CPSR alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $CPSR

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $CPSR
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G filed by Capstar Special Purpose Acquisition Corp.

      SC 13G - CAPSTAR SPECIAL PURPOSE ACQUISITION CORP. (0001805087) (Subject)

      9/20/21 4:14:46 PM ET
      $CPSR
      Business Services
      Finance

    $CPSR
    SEC Filings

    See more
    • SEC Form 25-NSE filed by Capstar Special Purpose Acquisition Corp.

      25-NSE - GELESIS HOLDINGS, INC. (0001805087) (Subject)

      1/14/22 9:04:44 AM ET
      $CPSR
      Business Services
      Finance
    • Capstar Special Purpose Acquisition Corp. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders

      8-K - CAPSTAR SPECIAL PURPOSE ACQUISITION CORP. (0001805087) (Filer)

      1/12/22 4:09:39 PM ET
      $CPSR
      Business Services
      Finance
    • SEC Form 425 filed by Capstar Special Purpose Acquisition Corp.

      425 - CAPSTAR SPECIAL PURPOSE ACQUISITION CORP. (0001805087) (Subject)

      1/10/22 6:26:59 AM ET
      $CPSR
      Business Services
      Finance

    $CPSR
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4: Cavanaugh Kathryn converted options into 12,825 shares, disposed of 12,825 shares and acquired 12,825 shares

      4 - GELESIS HOLDINGS, INC. (0001805087) (Issuer)

      1/18/22 5:00:38 PM ET
      $CPSR
      Business Services
      Finance

    $CPSR
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • PureTech Health plc – Half-Year Report

      Strong capital base with PureTech Level Cash and Cash Equivalents of $341.4 million1 and Consolidated Cash and Cash Equivalents of $365.9 million2 as of June 30, 2022, excluding up to $115.4 million added post-period3; Operational runway extended into Q1 2026 Significant advancement of PureTech's Wholly Owned Programs, with three clinical trials underway, four completed, and human proof-of-principle achieved for a key PureTech platform Excellent progress across the Founded Entities, including Karuna's positive topline Phase 3 results for KarXT in schizophrenia, Akili's Nasdaq listing and Gelesis' commercial progress with Plenity®4 in the post-period, and four clinical data publications ac

      8/25/22 2:07:00 AM ET
      $CPSR
      $DNAA
      $GLS
      $KRTX
      Business Services
      Finance
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • PureTech Founded Entity Gelesis Announces Clinical Data Demonstrating Weight Loss with GS200 in Adults with Prediabetes and Type 2 Diabetes Presented at the European Congress on Obesity 2022

      Gelesis' six-month study of weight loss in adults with overweight or obesity who have prediabetes or type 2 diabetes met both of its primary endpoints: the proportion of participants who achieved at least 5% body weight loss (i.e., "Categorical") and the change in body weight after six months of therapy GS200 demonstrated a highly favorable Categorial weight loss response and tolerability in a population that often struggles to lose weight and is at high risk for obesity-related complications; the overall incidence of adverse events (AEs) in adults treated with GS200 was similar to the placebo group ~6 out of 10 GS200-treated adults achieved at least 5% weight loss ("Responders"), losing

      5/4/22 6:35:00 AM ET
      $CPSR
      $GLS
      $PRTC
      Business Services
      Finance
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • PureTech Founded Entity Gelesis Announces its Proprietary Superabsorbent Hydrogel Induced Beneficial Changes to the Gut Microbiota and Expanded Akkermansia, a Bacterial Species Associated with Gut Health and Weight Loss, in New Study

      New preclinical data presented today at the World of Microbiome Conference suggest adding superabsorbent hydrogel to a high-fat "western-like" diet prevents unfavorable changes in the communities of gut bacteria associated with diet-induced weight gain PureTech Health plc (NASDAQ:PRTC, LSE: PRTC))) ("PureTech" or the "Company"), a clinical-stage biotherapeutics company announced that its Founded Entity, Gelesis Holdings, Inc. (NYSE:GLS) ("Gelesis), released today a poster prPesentation at the World of Microbiome annual meeting in Vienna. The preclinical study showed administration of one of Gelesis' proprietary superabsorbent hydrogels, Gel-B, significantly shifted the composition of the m

      4/29/22 6:05:00 AM ET
      $CPSR
      $GLS
      $PRTC
      Business Services
      Finance
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care